<DOC>
	<DOCNO>NCT02978716</DOCNO>
	<brief_summary>This study investigate potential clinical benefit trilaciclib ( G1T28 ) preserve bone marrow immune system , enhance chemotherapy antitumor efficacy administer prior carboplatin gemcitabine ( GC therapy ) patient metastatic triple negative breast cancer . The study open-label approximately 90 patient randomly assign ( 1:1:1 fashion ) 1 3 follow treatment group : - Group 1 : GC therapy ( Days 1 8 21-day cycle ) ( n=30 ) - Group 2 : GC therapy ( Days 1 8 ) plus trilaciclib ( G1T28 ) Days 1 8 21-day cycle ( n=30 ) - Group 3 : GC therapy ( Days 2 9 ) plus trilaciclib ( G1T28 ) Days 1 , 2 , 8 , 9 21-day cycle ( n=30 ) The study include 3 study phase : Screening Phase , Treatment Phase , Survival Follow-up Phase . The Treatment Phase begin day first dose study treatment complete Post-Treatment Visit .</brief_summary>
	<brief_title>Trilaciclib ( G1T28 ) , CDK 4/6 Inhibitor , Combination With Gemcitabine Carboplatin Metastatic Triple Negative Breast Cancer ( mTNBC )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Confirmed diagnosis HRnegative , HER2negative ( TNBC ) breast cancer Available TNBC diagnostic tumor tissue ( archived tissue allow ) Measurable disease define RECIST , Version 1.1 ECOG performance status 0 1 Adequate organ function Predicted life expectancy 3 month More 1 prior chemotherapy regimen locally recurrent metastatic TNBC Prior treatment locally recurrent metastatic breast cancer gemcitabine , carboplatin , cisplatin ( previous adjuvant/neoadjuvant chemotherapy carboplatin , cisplatin , gemcitabine allow â‰¥ 12 month elapse date last adjuvant/neoadjuvant chemotherapy administration first document local distant disease recurrence ) Less 12 month date last adjuvant chemotherapy administration ( curative intent ) first document local distant disease recurrence . Active uncontrolled/symptomatic CNS metastasis , carcinomatous meningitis , leptomeningeal disease Investigational drug within 30 day first trilaciclib ( G1T28 ) dose Concurrent radiotherapy , radiotherapy within 14 day first trilaciclib ( G1T28 ) dose Cytotoxic chemotherapy within 3 week first trilaciclib ( G1T28 ) dose Prior hematopoietic stem cell bone marrow transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>CDK 4/6 Inhibitor</keyword>
	<keyword>Triple Negative Breast Cancer</keyword>
</DOC>